Anmelden Kostenlos registrieren

Affimed N.V Vermögensrendite

Was ist das Vermögensrendite von Affimed N.V?

Vermögensrendite von Affimed N.V. ist -22.46%

Was ist die Definition von Vermögensrendite?



Die Vermögensrendite gibt an, wie rentabel die Vermögenswerte eines Unternehmens bei der Erzielung von Einnahmen sind. Sie wird berechnet, indem das Nettoeinkommen durch die durchschnittliche Bilanzsumme geteilt wird.

The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.

Vermögensrendite von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Affimed N.V

Was macht Affimed N.V?

affimed (symbol: afmd) is a nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. immuno-oncology represents a highly promising approach to cancer treatment that seeks to harness the body’s own immune defenses to attack and destroy tumor cells. natural killer cells, or nk-cells, and t-cells belong to the most potent cells of the human defense arsenal. affimed’s proprietary, next-generation bispecific antibodies, termed tandabs®, are designed to bring nk-cells or t-cells into close proximity to cancer cells that ultimately triggers a signal cascade that leads to the destruction of cancer cells. due to their novel tetravalent tandem architecture, which provides for four binding domains, the tandabs bind to specific targets on immune and cancer cells with high affinity. in addition, tandabs exhibit kinetic properties allowing the administration as regular intravenous infusion and fine-tuning of dosing. affimed beli

Unternehmen mit vermögensrendite ähnlich Affimed N.V